Novel Insulin Sensitizers to Treat Type 2 Diabetes
Verva’s lead phase 2a clinical product VVP808 is an insulin sensitizer with a novel mode-of-action different to existing diabetes therapies. VVP808 provides an important new line of treatment for that may be used to complement - and hopefully supplant - existing drug therapies. Verva also has an active discovery program to identify potent next-generation molecules based on VVP808. Initial screening has already identified 3 new scaffolds for continued evaluation and development
Prevention and Treatment of Obesity and Related Complications
Verva has generated preclinical proof-of-concept with 2 technologies that act directly in adipose tissue to prevent de novo fat cell formation. Verva Fat Blockers represent a novel approach to obesity therapy with multiple potential indications, including weight and fat loss in obesity; prevent of weight and fat re-gain after diet or surgery; adjuvant therapy to prevent drug-induced weight gain; and prevention and reversal of diabetes.
GES Discovery Platform
Verva’s proprietary Gene Expression Signature (GES) platform provides for rapid screening of compound libraries in a target- and mechanism-independent manner, allowing identification of diabetes therapeutics with novel and varied modes-of action. Different GES types may be employed to identify medications that are optimized to specific sub-groups of diabetic patients, providing for improved, personalized diabetes medicines. The GES platform is an ideal tool with which to unlock previously-unknown value in compound libraries; to identify new applications for marketed molecules; and to reposition clinical candidates that might have been unsuccessful in other indications.
